Ratings Avantor, Inc.

Equities

AVTR

US05352A1007

Market Closed - Nyse Other stock markets 04:00:02 2024-04-25 pm EDT			5-day change	1st Jan Change
25.15 ^USD	-1.22%		+3.50%	+10.16%

Apr. 18	Deutsche Bank Adjusts Price Target on Avantor to $25 From $23, Keeps Hold Rating	MT
Apr. 10	Beauty Health Names Sheri Lewis as Chief Supply Chain, Operations Officer	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

The company's profit outlook over the next few years is a strong asset.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The group shows a rather high level of debt in proportion to its EBITDA.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 34.72 times its estimated earnings per share for the ongoing year.
The company's enterprise value to sales, at 3.13 times its current sales, is high.
The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the past year, analysts have significantly revised downwards their profit estimates.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.	ESG Refinitiv
AVANTOR, INC.	+10.16%	17.08B	B
ABBOTT LABORATORIES	-2.92%	185B	C+
MEDTRONIC PLC	-3.80%	105B	C
BECTON, DICKINSON AND COMPANY	-5.48%	66.59B	A
DEXCOM, INC.	+11.22%	54.66B	B-
CENCORA, INC.	+16.74%	47.78B	B-
HOYA CORPORATION	+4.06%	41.26B	B+
WEST PHARMACEUTICAL SERVICES, INC.	+4.56%	26.95B	A-
METTLER-TOLEDO INTERNATIONAL, INC.	+1.64%	26.37B	B
TERUMO CORPORATION	+12.96%	24.8B	A-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes